Skopos Labs, Inc. Summit Therapeutics Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 1,918 shares of SMMT stock, worth $35,885. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,918
Previous 1,918
-0.0%
Holding current value
$35,885
Previous $36,000
11.11%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
270Shares Held
90.8MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$631 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$162 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$148 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$75.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$73.1 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.76B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...